Company Profile
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Latest News
Alphabet, Amazon, and Meta Will Spend Over $500 Billion on AI in 2026. Nvidia Collects a Huge Share.
Hankook iON Race Handles Tokyo's Day-to-Night Transition Across Two Races
Russell Reynolds Associates Announces Nick Fletcher as Australia Country Leader
Earnings To Watch: First Commonwealth Financial (FCF) Reports Q2 Results Tomorrow
Oil slips 4% after US, Iran pause fighting over weekend
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://samsungbiologics.com |
| Audit Risk | 1 |
| Board Risk | 5 |
| Overall Risk | 4 |
| Market Cap | 71.24T |
| Enterprise-to-Revenue | 14.5 |
| Enterprise-to-EBITDA | 25.07 |
| Earnings Date | 07/23/2026 |
| Earnings Call Date | |
| Earnings Average | 9,718 |
| Earnings Low | 8,964.8 |
| Earnings High | 10,666.02 |
| Revenue Average | 1.33T |
| Revenue Low | 1.27T |
| Revenue High | 1.38T |